Abstract
Purpose :
Evaluate the macular thickness and visual acuity after the treatment using aflibercept plus ranibizumab with dexamethasone intravitreal injection in diabetic macular edema’s eyes.
Methods :
Six groups randomly selected and submitted to alternating treatment with aflibercept (G1), ranibizumab (G2), aflibercept + dexamethasone (G3), ranibizumab + dexamethasone (G4), 2 aflibercept + 1 ranibizumabe + dexamethasone (G5) and 1 aflibercept + 2 ranibizumabe + dexamethasone (G6).
Groups randomly selected and submitted to alternating treatment with A (G1), R (G2), A+D (G3), R+D (G4), 2 A+1R+D (G5) and 1 A+2 R+D (G6). To evaluate and compare the efficacy of DME according to VA and MT. Were performed IVI in 24 eyes with formal indications of DME treatment. 1 application per month and monitoring with OCT on days 7 and 30 subsequent to application. After finished the aplications, every 30 days, OCT was performed .
All patients were glycemic controlled and after treatment with injections, panfotocoagulation was performed. After 3 months of initial treatment, there was recurrence of macular edema in 4 eyes and after 6 months another 3 eyes had macular edema. When the same initial treatment was repeated.
Results :
In G5 or G6 application there was a DME reduction of about 52.35% and 55.21%, 1 year after the third IVI. In G3 or G4 was 43.28% and 43.76%. The reduction was in G1 or G2 (32.82% and 30.23%) The VA observed a constant improvement, 2 lines (G1 and G2) and 4 lines (G3, G4, G5, G6).
Conclusions :
We can state through this study that the treatment of diabetic macular edema with anti-VEGF associated with corticosteroid has a greater benefit than the treatment with these single drugs, shown by optical coherence tomography.
Visual acuity increased with the association of drugs regardless of which antiangiogenic drug used.
This is a 2020 ARVO Annual Meeting abstract.